Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
uwlungman, ask yourself why all the manipulating: conversions, possible splits, all the uncertainty. I'm of the opinion that simpler is better for the small investor. Once they start throwing all of these possible scenarios into the mix it just leaves more to chance. IMO, just doesn't feel right; doesn't feel like it will work to my advantage.
Please, correct me if you think the company is showing some benevolence to their investors that have given them the capital to work with.
All4all, what do you mean 'this is going to be a CD'?
nick82, % gain still depends on the conversion rate coming out on the other side.
nick82, Does that mean you can buy in on 5/03 and submit those shares for the conversion on 5/04? I thought 5/04 was the date to submit common shares in order to qualify for the conversion. I didn't think that, "stock held by its shareholders as of the record date", meant the same thing.
nick82, The PR says $1 for 1000 shares valued @ $.001
"common shares of stock held by its shareholders as of the record date" What I'd like to know is by when?
Lifeline Biotechnologies, Inc. will offer to exchange its Series B Convertible Preferred Stock, to be valued by the Company at $1.00 per share, for common shares of stock held by its shareholders as of the record date, which the Company is valuing at $.001 per share, a premium to the current market price. This means for every 1,000 shares of common stock submitted to the Company for exchange, shareholders will receive one share of Series B Convertible Preferred Stock valued at $1.00 for future conversion purposes.
stockhound101, You may be on to something. Given their history of R/S action, this may be merely a new variation that gives them the ability to reel in a lot more fish. I'm not happy about being forced to be restricted. Also, I find the timing of this to be counter-productive, especially on top of all the dumping. We probably have been had. I'm resigned to that until I see the company showing us something to the contrary.
Thanks Strong! Sounds like you're not concerned about any kind of "scam" or "hassle" as some on the LBTN board have suggested.
Anything is better than having a R/S hanging over your head.
Supposedly the conversion of the shares protects them from effects of re-structuring. Hopefully, that's true.
Thanks again.
All4all, appreciate the candor; I was worried about the R/S as well. After x-number of years what are your options with the shares that were converted? i.e. can be converted back into common shares etc? Are all of the restrictions lifted all at once or are there stages? TIA
Lifeline Biotechnologies, Inc. Anybody have a clue on the best way to approach this scenario if you're holding or thinking of buying in?
Lifeline Biotechnologies, Inc. Authorizes Stock Exchange Program to Shareholders 8:31 AM ET – BusinessWire
Lifeline Biotechnologies, Inc. (Pink Sheets:LBTN) today announced the Company is offering a share exchange program to its common stock shareholders. Lifeline Biotechnologies, Inc. will offer to exchange its Series B Convertible Preferred Stock, to be valued by the Company at $1.00 per share, for common shares of stock held by its shareholders as of the record date, which the Company is valuing at $.001 per share, a premium to the current market price. This means for every 1,000 shares of common stock submitted to the Company for exchange, shareholders will receive one share of Series B Convertible Preferred Stock valued at $1.00 for future conversion purposes.
Current shareholders must have their shares into OTC Corporate Transfer Service Company by May 4, 2007, unless extended by the Company, in order to qualify for the exchange of common shares to Series B Convertible Preferred Shares. In order to qualify for the exchange, shareholders must submit a minimum of 100,000 shares of common stock. The Series B Convertible Preferred Stock will be protected from any future stock restructuring by the Company. For the complete terms and conditions of the stock exchange program, the Company will be posting particulars on its website www.lbtn.com. In addition, the Company will prepare and mail to its shareholders of record an Information Statement disclosing the terms and conditions of the exchange.
"We are very pleased to be able to offer our shareholders this exchange program. With the program announcement today, we are reaffirming our confidence and optimism in the long-term future of the Company. As more information becomes available, it will be provided on our website and/or through press releases," stated Jim Holmes, President of Lifeline Biotechnologies, Inc.
About Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of disease conditions. The Company's technologies, designed to assist in the early detection of cancers, deal with cutting-edge innovation to assist practicing physicians in the delivery of quality medical care. The First Warning System(TM), a process for assisting in the early detection of breast cancer, is continuing to be developed by the Company. More information is available at the company's website: www.lbti.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Exchange Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
To automatically receive instant updates, press releases and other information on this and other Big Apple Consulting USA companies, please visit www.bigappleconsulting.com/compro.php and download your FREE copy of Big Apple ComPro.
SOURCE: Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. Rodney Marvel, Investor Relations, 1-866-THE-APPL(E) www.lbtn.com
All4all, R U saying to lock in at that value by converting? Just looking for possible ways to move on this. Would not hold you responsible as if you advised me to do something; just want an opinion. TIA & GLTY
Anybody have a clue on the best way to approach this scenario if you're holding or thinking of buying in?
Lifeline Biotechnologies, Inc. Authorizes Stock Exchange Program to Shareholders
8:31 AM ET - BusinessWire
Lifeline Biotechnologies, Inc. (Pink Sheets:LBTN) today announced the Company is offering a share exchange program to its common stock shareholders. Lifeline Biotechnologies, Inc. will offer to exchange its Series B Convertible Preferred Stock, to be valued by the Company at $1.00 per share, for common shares of stock held by its shareholders as of the record date, which the Company is valuing at $.001 per share, a premium to the current market price. This means for every 1,000 shares of common stock submitted to the Company for exchange, shareholders will receive one share of Series B Convertible Preferred Stock valued at $1.00 for future conversion purposes.
Current shareholders must have their shares into OTC Corporate Transfer Service Company by May 4, 2007, unless extended by the Company, in order to qualify for the exchange of common shares to Series B Convertible Preferred Shares. In order to qualify for the exchange, shareholders must submit a minimum of 100,000 shares of common stock. The Series B Convertible Preferred Stock will be protected from any future stock restructuring by the Company. For the complete terms and conditions of the stock exchange program, the Company will be posting particulars on its website www.lbtn.com. In addition, the Company will prepare and mail to its shareholders of record an Information Statement disclosing the terms and conditions of the exchange.
"We are very pleased to be able to offer our shareholders this exchange program. With the program announcement today, we are reaffirming our confidence and optimism in the long-term future of the Company. As more information becomes available, it will be provided on our website and/or through press releases," stated Jim Holmes, President of Lifeline Biotechnologies, Inc.
About Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of disease conditions. The Company's technologies, designed to assist in the early detection of cancers, deal with cutting-edge innovation to assist practicing physicians in the delivery of quality medical care. The First Warning System(TM), a process for assisting in the early detection of breast cancer, is continuing to be developed by the Company. More information is available at the company's website: www.lbti.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Exchange Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
To automatically receive instant updates, press releases and other information on this and other Big Apple Consulting USA companies, please visit www.bigappleconsulting.com/compro.php and download your FREE copy of Big Apple ComPro.
SOURCE: Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. Rodney Marvel, Investor Relations, 1-866-THE-APPL(E) www.lbtn.com
Anybody have a clue on the best way to approach this scenario if you're holding or thinking of buying in?
Lifeline Biotechnologies, Inc. Authorizes Stock Exchange Program to Shareholders
8:31 AM ET - BusinessWire
Lifeline Biotechnologies, Inc. (Pink Sheets:LBTN) today announced the Company is offering a share exchange program to its common stock shareholders. Lifeline Biotechnologies, Inc. will offer to exchange its Series B Convertible Preferred Stock, to be valued by the Company at $1.00 per share, for common shares of stock held by its shareholders as of the record date, which the Company is valuing at $.001 per share, a premium to the current market price. This means for every 1,000 shares of common stock submitted to the Company for exchange, shareholders will receive one share of Series B Convertible Preferred Stock valued at $1.00 for future conversion purposes.
Current shareholders must have their shares into OTC Corporate Transfer Service Company by May 4, 2007, unless extended by the Company, in order to qualify for the exchange of common shares to Series B Convertible Preferred Shares. In order to qualify for the exchange, shareholders must submit a minimum of 100,000 shares of common stock. The Series B Convertible Preferred Stock will be protected from any future stock restructuring by the Company. For the complete terms and conditions of the stock exchange program, the Company will be posting particulars on its website www.lbtn.com. In addition, the Company will prepare and mail to its shareholders of record an Information Statement disclosing the terms and conditions of the exchange.
"We are very pleased to be able to offer our shareholders this exchange program. With the program announcement today, we are reaffirming our confidence and optimism in the long-term future of the Company. As more information becomes available, it will be provided on our website and/or through press releases," stated Jim Holmes, President of Lifeline Biotechnologies, Inc.
About Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of disease conditions. The Company's technologies, designed to assist in the early detection of cancers, deal with cutting-edge innovation to assist practicing physicians in the delivery of quality medical care. The First Warning System(TM), a process for assisting in the early detection of breast cancer, is continuing to be developed by the Company. More information is available at the company's website: www.lbti.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Exchange Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
To automatically receive instant updates, press releases and other information on this and other Big Apple Consulting USA companies, please visit www.bigappleconsulting.com/compro.php and download your FREE copy of Big Apple ComPro.
SOURCE: Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. Rodney Marvel, Investor Relations, 1-866-THE-APPL(E) www.lbtn.com
Anybody have a clue on the best way to approach this scenario if you're holding or thinking of buying in?
Get fearful on the greed; get greedy on the fear.
Damn, that's good! I wish I had coined that.
That's alright though; I'm trackin'!!
uwlungman, Dumpage?
stockhound101, Thanks! I will try to get a clearer understanding of how the company plans to implement their advancements and become a major presence in this field.
LBTN. Lifeline Biotechnologies, Inc. Comments on the Shortcomings of the Early Detection of Breast Cancer as Reported in a National Cancer Institute Study
4/3/2007 8:30:07 AM
RENO, Nev., Apr 03, 2007 (BUSINESS WIRE) -- Today,
Dr. Louis Keith, Vice President and Medical Director of Lifeline Biotechnologies, Inc. (Pink Sheets:LBTN), commented on an article published online by the New England Journal of Medicine yesterday. "This publication is a top medical journal and the reported data is excellent. The study, conducted at 25 U.S. test sites, was paid for by the National Institutes of Health. As a result, the American Cancer Society suggests that high-risk women and those with diagnosed breast cancer in one breast get an MRI. This procedure can cost $2,000 or more which is not reimbursable by Medicare or private insurance carriers."
The American Cancer Society said MRI screening was cost effective for the approximately 650,000 women in the high-risk group or one percent of the 65 million women over age 40 recommended to receive mammograms every one to two years. This additional burden will cost an additional $1.3 billion to our already overtaxed health care system.
Of the vast majority of patients who have cancer in a single breast at the time of diagnosis, only about 10 percent go on to develop cancer in the opposite breast. When that happens, patients face a second round of treatment, which can include surgery, chemotherapy or radiation.
Jim Holmes, Lifeline's CEO, commented, "Reading between the lines of this new report reconfirms what Lifeline has maintained for the past 20 years: Mammographic screening leaves much to be desired."
Dr. Keith contended, "Any time a patient must rely on human interpretation of imaging data the door is open to error. The interpreter is usually no better than his mentor, and the interpretative results can be influenced by human variables, such as fatigue, etc., that can easily affect diagnostic interpretation. Interpretation of clinical data from any medical test is critical, particularly when attempting to detect a disease as deadly as cancer. These interpretations are what all physicians must continually depend upon in the practice of medicine. Because of this problem, Lifeline has worked to develop a breast cancer screening system that can eliminate the human error factor."
Dr. Keith further stated, "Lifeline appears finally to have developed a technology to identify breast cancer at its earliest stage. Some clinical testing still lies ahead of us, but the promise is clear: We are developing a technology that may well be superior to any modality presently used in breast cancer screening. The recent NCI-sponsored study looked at 969 women with recently diagnosed cancer in one breast but no cancer in the opposite breast based on a mammogram and clinical exam. All women in the study received an MRI of the opposite breast, which detected possible cancer in 121 women. A biopsy confirmed cancer in only 30 women, or 3.1 percent of those in the trial. For the remaining 91 women, biopsies were negative. This evidence demonstrates that even with an MRI, 91 unnecessary biopsies were performed, a discrepancy related to human error."
Mr. Holmes continued, "It is Lifeline's challenge to eliminate or limit these errors through the use of computer interpretation. If First Warning(TM) test data results continue to hold their accuracy, as we believe they will, after FDA approval we plan to market First Warning(TM) as an adjunct to mammography. If fully employed in breast cancer screening, it could possibly eliminate 91% of the unnecessary breast biopsies preformed each year, at a savings of approximately $2.8 billion per annum, and it could conceivably eliminate the need for the suggested additional MRIs, or another $1.3 billion. Of the approximately $138 billion spent on cancer each year, Lifeline could conceivably earn approximately $3.5 billion annually in computer reading service revenue while saving the health care service up to an additional $4.1 billion."
About Lifeline Biotechnologies, Inc.:
Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's technologies, designed to assist in the early detection of cancers, deal with cutting-edge innovation to assist practicing physicians in the delivery of quality medical care.
SAFE HARBOR:
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Exchange Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc.
Rodney Marvel, Investor Relations, 1-866-THE-APPLE
www.lbtn.com
Copyright Business Wire 2007
Thanks, CREEP. Always wanted to say that.
B_5, If U R correct on your prediction I will have a net gain of about $413,000 or 5,900%.
We'll see if anyone can fill at '1' today.
Should be interesting to see the reaction to PR.
mcaptrdr (or anybody),
What I was getting at in my other post was that Lifeline's contribution to diagnostics still relies on the methods of doing the imagery currently being utilized.
Is that correct or not?
I understand that there is a great gap to be filled by Lifeline Biotechnologies' advancements. Is that technology strictly software related? In other words, is what they're patenting the methods of taking imagery and applying algorithmic type modeling in order to eliminate the unnecessary biopsies?
Some on this board alluded to some device being developed and the imagery interpreting scenario certainly wouldn't imply that.
Lifeline Biotechnologies, Inc. Comments on the Shortcomings of the Early Detection of Breast Cancer as Reported in a National Cancer Institute Study
22 minutes ago - BusinessWire
Today, Dr. Louis Keith, Vice President and Medical Director of Lifeline Biotechnologies, Inc. (Pink Sheets:LBTN), commented on an article published online by the New England Journal of Medicine yesterday. "This publication is a top medical journal and the reported data is excellent. The study, conducted at 25 U.S. test sites, was paid for by the National Institutes of Health. As a result, the American Cancer Society suggests that high-risk women and those with diagnosed breast cancer in one breast get an MRI. This procedure can cost $2,000 or more which is not reimbursable by Medicare or private insurance carriers."
The American Cancer Society said MRI screening was cost effective for the approximately 650,000 women in the high-risk group or one percent of the 65 million women over age 40 recommended to receive mammograms every one to two years. This additional burden will cost an additional $1.3 billion to our already overtaxed health care system.
Of the vast majority of patients who have cancer in a single breast at the time of diagnosis, only about 10 percent go on to develop cancer in the opposite breast. When that happens, patients face a second round of treatment, which can include surgery, chemotherapy or radiation.
Jim Holmes, Lifeline's CEO, commented, "Reading between the lines of this new report reconfirms what Lifeline has maintained for the past 20 years: Mammographic screening leaves much to be desired."
Dr. Keith contended, "Any time a patient must rely on human interpretation of imaging data the door is open to error. The interpreter is usually no better than his mentor, and the interpretative results can be influenced by human variables, such as fatigue, etc., that can easily affect diagnostic interpretation. Interpretation of clinical data from any medical test is critical, particularly when attempting to detect a disease as deadly as cancer. These interpretations are what all physicians must continually depend upon in the practice of medicine. Because of this problem, Lifeline has worked to develop a breast cancer screening system that can eliminate the human error factor."
Dr. Keith further stated, "Lifeline appears finally to have developed a technology to identify breast cancer at its earliest stage. Some clinical testing still lies ahead of us, but the promise is clear: We are developing a technology that may well be superior to any modality presently used in breast cancer screening. The recent NCI-sponsored study looked at 969 women with recently diagnosed cancer in one breast but no cancer in the opposite breast based on a mammogram and clinical exam. All women in the study received an MRI of the opposite breast, which detected possible cancer in 121 women. A biopsy confirmed cancer in only 30 women, or 3.1 percent of those in the trial. For the remaining 91 women, biopsies were negative. This evidence demonstrates that even with an MRI, 91 unnecessary biopsies were performed, a discrepancy related to human error."
Mr. Holmes continued, "It is Lifeline's challenge to eliminate or limit these errors through the use of computer interpretation. If First Warning(TM) test data results continue to hold their accuracy, as we believe they will, after FDA approval we plan to market First Warning(TM) as an adjunct to mammography. If fully employed in breast cancer screening, it could possibly eliminate 91% of the unnecessary breast biopsies preformed each year, at a savings of approximately $2.8 billion per annum, and it could conceivably eliminate the need for the suggested additional MRIs, or another $1.3 billion. Of the approximately $138 billion spent on cancer each year, Lifeline could conceivably earn approximately $3.5 billion annually in computer reading service revenue while saving the health care service up to an additional $4.1 billion."
imsickandtired,
Thanks for the response: I hope you're right and pretty sure that you are. Hope you feel better soon.
Go-Brewers-GO! ...will be backin' possibly the best starting rotation in MLB this season.
I'm OUT.
B_5, back away from the crack-pipe...
try to settle in for a wee bit of reality.
Don't make me worry about you so.
Yea, it's opening day so I'll froget about this and go get a little blurry-eyed watchin' the prima'donnas of summer.
You could air it out. I don't have FiOS.
Anybody's gut feeling on how long we could be stuck here, and how much more dumping yet ??
Thanks A Bunch, 777777777777777777777777777777777777777777
What's holding up GSPN from running on news?
GPSN news $16.5mm contract; min for each of 5 yrs.
Esprit Financial Group Inc. (Esprit) (CHNW.PK) Launches Forex Trading Website
7:00 AM ET - PR Newswire...
...
The Company is pleased to announce that its Forex Trading service is now open for business at its permanent URL location, www.cashnow.com. The Win Trader Mini Platform offers a 2 pip spread on major currency pairs. Importantly, there is no dealing desk. All trades are processed electronically on a streaming pass-through basis. This eliminates price manipulation that can lag the actual interbank market and cut into traders' profits. Clients can also benefit from the fact that there are no interruptions or slowdowns in trading during major news or market reports that can affect trading prices.
With the Forex service moving to www.cashnow.com, there have been additional location changes to the Company's other product divisions. The Cash Now Payday Loan Business Aggregation website can now be found at www.cashnow.org. The Company's sub-prime loan facilitation service, featuring a real-time online booking engine, is now located at www.cashnow.net.
The launch of the Forex website is a significant business milestone, as Cash Now executes on its diversified financial products development program. In addition to the launch of this North American based Forex service, the launch date of a UK based website remains on target for May 15, 2007. The Company also plans to launch an additional website serving the Asian or the Asiana markets.
Richard Sciacchetano, head of Esprit's Forex Trading division comments, "We are coming to market with a terrific product. The retail forex market is relatively new. As with most such disruptive business developments, the landscape is more than a little like the Wild West. Most forex websites have taken advantage of retail traders by manipulating data in a manner that is technically not misleading, but proves frustrating to traders as they start to wonder why their trades don't match the actual movements of the interbank market. As an Introducing Broker for Advanced markets, Inc, we can assure our clients that there is no smoke and mirrors here. All trades are handled on a streaming pass-through basis. There is no dealing desk, no intermediary manipulation of pips before data reaches the trader. We believe that seasoned day traders will increasingly find that our products are truly fair, honest and transparent. We expect to make a lot of long term relationships with our client's".
CEO Garr Winters noted: "It is important for us that we have met our established deadline for the launch. It has been our intent to keep all of our shareholders and stakeholder groups fully apprised of business developments, and our approach to growth. It is vital that we hit the target every time on every front. We are intent on building credibility, and that means ensuring that any announcements made are carried through to completion, as promised and on time. We're looking down the track, and we see tremendous growth full potential for this organization. Our senior management team is truly excellent, and includes industry pioneers and innovators in our key business sectors. Their past accomplishments are real, and we expect that to continue in the future".
Winters added, "Of course, this doesn't mean that it's just business as usual today. We'll take a breather for a couple of hours, and celebrate the moment. I have to thank all of our people who have managed this project so well, which also includes Advanced Markets, Inc. who have been tremendously supportive and accommodating as we ramped up to this launch date".
Esprit Financial Group Inc. (Esprit) (CHNW.PK) Launches Forex Trading Website
7:00 AM ET - PR Newswire...
...
The Company is pleased to announce that its Forex Trading service is now open for business at its permanent URL location, www.cashnow.com. The Win Trader Mini Platform offers a 2 pip spread on major currency pairs. Importantly, there is no dealing desk. All trades are processed electronically on a streaming pass-through basis. This eliminates price manipulation that can lag the actual interbank market and cut into traders' profits. Clients can also benefit from the fact that there are no interruptions or slowdowns in trading during major news or market reports that can affect trading prices.
With the Forex service moving to www.cashnow.com, there have been additional location changes to the Company's other product divisions. The Cash Now Payday Loan Business Aggregation website can now be found at www.cashnow.org. The Company's sub-prime loan facilitation service, featuring a real-time online booking engine, is now located at www.cashnow.net.
The launch of the Forex website is a significant business milestone, as Cash Now executes on its diversified financial products development program. In addition to the launch of this North American based Forex service, the launch date of a UK based website remains on target for May 15, 2007. The Company also plans to launch an additional website serving the Asian or the Asiana markets.
Richard Sciacchetano, head of Esprit's Forex Trading division comments, "We are coming to market with a terrific product. The retail forex market is relatively new. As with most such disruptive business developments, the landscape is more than a little like the Wild West. Most forex websites have taken advantage of retail traders by manipulating data in a manner that is technically not misleading, but proves frustrating to traders as they start to wonder why their trades don't match the actual movements of the interbank market. As an Introducing Broker for Advanced markets, Inc, we can assure our clients that there is no smoke and mirrors here. All trades are handled on a streaming pass-through basis. There is no dealing desk, no intermediary manipulation of pips before data reaches the trader. We believe that seasoned day traders will increasingly find that our products are truly fair, honest and transparent. We expect to make a lot of long term relationships with our client's".
CEO Garr Winters noted: "It is important for us that we have met our established deadline for the launch. It has been our intent to keep all of our shareholders and stakeholder groups fully apprised of business developments, and our approach to growth. It is vital that we hit the target every time on every front. We are intent on building credibility, and that means ensuring that any announcements made are carried through to completion, as promised and on time. We're looking down the track, and we see tremendous growth full potential for this organization. Our senior management team is truly excellent, and includes industry pioneers and innovators in our key business sectors. Their past accomplishments are real, and we expect that to continue in the future".
Winters added, "Of course, this doesn't mean that it's just business as usual today. We'll take a breather for a couple of hours, and celebrate the moment. I have to thank all of our people who have managed this project so well, which also includes Advanced Markets, Inc. who have been tremendously supportive and accommodating as we ramped up to this launch date".
UW_lm, are any in use currently?
Does anyone have a quick primer on LBTN history? TIA
In the past 10-12 years has Lifeline actually brought product that they developed for the health care industry which was actually used to either compliment or replace other devices for diagnostics?
Have they marketed software that would provide simulation or modeling the effects of treatment on different types of malignant cells?
The track record should be expressed here to reinforce the notion that Lifeline can actually bring a concept to a fully developed usable form as opposed to merely having ideas which are researched at infinitum and never coming to any feasible conclusion.
I guess what I'm trying to say that we need examples of tangible value.
By how many weeks has the company prolonged getting off the bottom with their share (re)structure?
What chance do we have of AS increase?
Steve,
As per your request, please find below share structure of lbtn.
Total Outstanding: 9,017,346,071
Total Outstanding Restricted: 110,183,570
Total Outstanding Non Restricted: 8,907,162,501
If you have any questions feel free to contact me.
Regards,
Toni Zaks
Administrative Director
OTC CORPORATE TRANSFER SERVICE CO.
52 MAPLE RUN DRIVE, JERICHO, NY 11753
516-932-2080 OFFICE
516-932-2078 FAX
ASK back up to 2, hhhhHwweeeewHhhhhhhh!
I know.
That's vague.
Maybe some specifics would stop the exodus.
What time frame are we talking about here?
You think ?
Who do you think is doing all the buying down here ?